PPAR-γ in the Cardiovascular System

Peroxisome proliferator-activated receptor-γ (PPAR-γ), an essential transcriptional mediator of adipogenesis, lipid metabolism, insulin sensitivity, and glucose homeostasis, is increasingly recognized as a key player in inflammatory cells and in cardiovascular diseases (CVD) such as hypertension, cardiac hypertrophy, congestive heart failure, and atherosclerosis. PPAR-γ agonists, the thiazolidinediones (TZDs), increase insulin sensitivity, lower blood glucose, decrease circulating free fatty acids and triglycerides, lower blood pressure, reduce inflammatory markers, and reduce atherosclerosis in insulin-resistant patients and animal models. Human genetic studies on PPAR-γ have revealed that functional changes in this nuclear receptor are associated with CVD. Recent controversial clinical studies raise the question of deleterious action of PPAR-γ agonists on the cardiovascular system. These complex interactions of metabolic responsive factors and cardiovascular disease promise to be important areas of focus for the future.

• Publication year

  2007

• Venue

  PPAR Research

• Publication date

  2007-12-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2008/745804PMID 18288291PMCID 2225467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.

  2007cited by this paper
• Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.

  2007influential reference
• PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007influential reference
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007influential reference
• Macrophage-specific PPARγ controls alternative activation and improves insulin resistance

  2007cited by this paper
• Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy.

  2006influential reference
• Peroxisome proliferator-activated receptor-γ ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia

  2006cited by this paper
• Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients.

  2006cited by this paper
• Are thiazolidinediones good or bad for the heart?

  2006cited by this paper
• The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.

  2006cited by this paper
• Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand.

  2005cited by this paper
• Troglitazone, a PPAR-γ activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-α

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

  2005cited by this paper
• Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator–Activated Receptor-γ Both Induce Cardiac Hypertrophy in Mice

  2005influential reference
• PPARγ in endothelial cells influences high fat diet-induced hypertension

  2005influential reference
• Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

  2005influential reference
• A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms.

  2005influential reference
• Retinoid X receptor heterodimers in the metabolic syndrome.

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal

  2005influential reference
• The metabolic syndrome: a global public health problem and a new definition.

  2005cited by this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005influential reference
• The many faces of PPARgamma.

  2005cited by this paper
• Metabolic syndrome: what is it and what are the implications?

  2005cited by this paper
• Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries.

  2005cited by this paper
• Influence of metabolic syndrome on hypertension‐related target organ damage

  2005cited by this paper
• PPARs: therapeutic targets for metabolic disease.

  2005cited by this paper
• A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ

  2005cited by this paper
• A Dominant Negative Peroxisome Proliferator-activated Receptor-γ Knock-in Mouse Exhibits Features of the Metabolic Syndrome*

  2005cited by this paper
• Retinoid x receptor heterodimers in the metabolic syndrome.

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• PPARgamma in endothelial cells influences high fat diet-induced hypertension.

  2005cited by this paper
• Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects

  2005cited by this paper
• Metabolic syndrome.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor γ ligand

  2005cited by this paper
• Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

  2004cited by this paper
• Anoxia-Reoxygenation Stimulates Collagen Type-I and MMP-1 Expression in Cardiac Fibroblasts: Modulation by the PPAR-γ Ligand Pioglitazone

  2004cited by this paper
• Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells

  2004cited by this paper
• An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats

  2004cited by this paper
• Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.

  2004influential reference
• Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-&ggr; Ligand Pioglitazone

  2004cited by this paper
• Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study).

  2004cited by this paper
• Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.

  2004cited by this paper
• Insulin resistance and cardiovascular disease: the role of PPARγ activators beyond their anti-diabetic action

  2004cited by this paper
• Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA

  2004cited by this paper
• Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.

  2004cited by this paper
• Peroxisome proliferator-activated receptor γ in diabetes and metabolism

  2004cited by this paper
• Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle

  2003cited by this paper
• Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells.

  2003cited by this paper
• Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

  2003cited by this paper
• Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass*

  2003cited by this paper
• Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor &ggr; in Vascular Smooth Muscle Cells

  2003cited by this paper
• Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Muscle-specific Pparg deletion causes insulin resistance

  2003cited by this paper
• Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.

  2003cited by this paper
• Cardiac hypertrophy: the good, the bad, and the ugly.

  2003cited by this paper
• Rosiglitazone (PPARγ‐agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes–atherosclerosis mouse model

  2003cited by this paper
• Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

  2003cited by this paper
• Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

  2003cited by this paper
• Peroxisome proliferator-activated receptor γ inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells

  2003cited by this paper
• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

  2002cited by this paper
• Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

  2002cited by this paper
• Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux

  2002cited by this paper
• An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis*

  2002cited by this paper
• PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.

  2002cited by this paper
• A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy

  2002cited by this paper
• Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma.

  2002cited by this paper
• Pioglitazone, a Peroxisome Proliferator–Activated Receptor- Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.

  2002cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Mixed signals in heart failure: cancer rules.

  2002cited by this paper
• A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.

  2002cited by this paper
• Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused Rats: Role of Peroxisome Proliferator–Activated Receptor-&ggr;

  2002cited by this paper
• Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study.

  2002cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo

  2002cited by this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-&ggr; Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

  2002cited by this paper
• The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance.

  2001cited by this paper
• PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth.

  2001cited by this paper
• Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

  2001cited by this paper
• Atherosclerosis The Road Ahead

  2001cited by this paper
• Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.

  2001cited by this paper
• A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001influential reference
• Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes

  2001cited by this paper
• Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL

  2001cited by this paper
• The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance*

  2001cited by this paper
• PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth*

  2001cited by this paper
• A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis

  2001cited by this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE

  2001cited by this paper
• Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice

  2001cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper

• Integrated MicroRNA–mRNA Sequencing Analysis Identifies Regulators and Networks Involved in Feline Hypertrophic Cardiomyopathy

  2025cites this paper
• Cardioprotective Effects of SAR Through Attenuating Cardiac-Specific Markers, Inflammatory Markers, Oxidative Stress, and Anxiety in Rats Challenged with 5-Fluorouracil

  2025cites this paper
• Gastrodia elata Blume: A review of its mechanisms and functions on cardiovascular systems.

  2023cites this paper
• Adriamycin downregulates the expression of KLF4 in cardiomyocytes in vitro and contributes to impaired cardiac energy metabolism in Adriamycin-induced cardiomyopathy

  2023cites this paper
• The medicinal perspective of 2,4‐thiazolidinediones based ligands as antimicrobial, antitumor and antidiabetic agents: A review

  2022cites this paper
• Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease

  2021cites this paper
• Evaluation of peroxisome proliferator-activated receptor-gamma (Ppar-γ) and metabolic dysfunction among hypertensive nigerians

  2021cites this paper
• Citri Reticulatae Pericarpium alleviates postmyocardial infarction heart failure by upregulating PPARγ expression

  2021cites this paper
• Nephroprotective effect of Combretum micranthum G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: In-vivo and In-silico experiments.

  2020cites this paper
• Lipid parameters and vitamin A modify cardiovascular risk prediction by plasma neopterin

  2020cites this paper
• Impact of chrysin on the molecular mechanisms underlying diabetic complications

  2019cites this paper
• Is pulmonary vascular disease reversible with PPAR ɣ agonists?

  2018cites this paper
• Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance

  2018cites this paper
• Time-dependent LXR/RXR pathway modulation characterizes capillary remodeling in inflammatory corneal neovascularization

  2018cites this paper
• PPARγ Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats.

  2017cites this paper
• Marine collagen peptides reduce endothelial cell injury in diabetic rats by inhibiting apoptosis and the expression of coupling factor 6 and microparticles

  2017cites this paper
• PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis

  2017cites this paper
• Biological Actions of PPAR-in Health and Disease

  2017cites this paper
• PPAR-gamma Signaling in Metabolic Homeostasis

  2016influential citation
• Familial partial lipodystrophy with gene mutation in both LMNA and PPARG : report of a case and review of literature

  2016cites this paper
• Loss of PPARγ in endothelial cells leads to impaired angiogenesis

  2016cites this paper
• Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice

  2015cites this paper
• Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs

  2015cites this paper
• Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue

  2015cites this paper
• Thymoquinone Protects against Myocardial Ischemic Injury by Mitigating Oxidative Stress and Inflammation

  2015cites this paper
• Activation of PPAR-γ ameliorates pulmonary arterial hypertension via inducing heme oxygenase-1 and p21(WAF1): an in vivo study in rats.

  2014cites this paper
• Analysis of Follicular Fluid Retinoids in Women Undergoing In Vitro Fertilization

  2013cites this paper
• Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study

  2013cites this paper
• L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression.

  2013cites this paper
• N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress.

  2013cites this paper
• Disorders of Sodium Balance

  2012cites this paper
• Selective Angiotensin Type 1 Receptor Antagonists as Peroxisome Proliferator - Actived Receptor modulators

  2012cites this paper
• The expression receptor of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA in human aorta compared to left ventricle in patients with coronary artery disease without diabetes

  2012cites this paper
• HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells.

  2011cites this paper
• Anti‐Stroke Profile of Thiazolidin‐4‐One Derivatives in Focal Cerebral Ischemia Model in Rat

  2011cites this paper
• 53 – Pharmacologic Modification of Acute Cerebral Ischemia

  2011cites this paper
• Rosiglitazone protects diabetic rats from liver destruction

  2011cites this paper
• Advances in the treatment of type 2 diabetes mellitus.

  2011cites this paper
• Trans–trans Conjugated Linoleic Acid Enriched Soybean Oil Reduces Fatty Liver and Lowers Serum Cholesterol in Obese Zucker Rats

  2011cites this paper
• Neuroprotection by rosiglitazone in transient focal cerebral ischemia might not be mediated by glutamate transporter‐1#

  2011cites this paper
• Elevated myocardial Na+/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy.

  2010cites this paper
• Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage.

  2010cites this paper
• Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man

  2010cites this paper
• A clinical update on peroxisome proliferator-activated receptors

  2010cites this paper
• PPARs in the Renal Regulation of Systemic Blood Pressure

  2010cites this paper
• Cellular and Molecular Changes Associated With Inhibitory Effect of Pioglitazone on Neointimal Growth in Patients With Type 2 Diabetes After Zotarolimus-Eluting Stent Implantation

  2010cites this paper
• Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ.

  2010cites this paper
• Eicosanoids and cancer

  2010cites this paper
• Mononuclear Cell Transcriptome Response after Sustained Virgin Olive Oil Consumption in Humans: An Exploratory Nutrigenomics Study

  2009cites this paper
• PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer

  2009cites this paper
• Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes

  2009influential citation
• Vascular Smooth Muscle Cell–Selective Peroxisome Proliferator–Activated Receptor-γ Deletion Leads to Hypotension

  2009cites this paper
• Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization.

  2009cites this paper
• Protective effect of ghrelin on left ventricular remodeling in spontaneously hypertensive rats is associated with the peroxisome proliferator-activated receptor gamma-dependent pathway.

  2008cites this paper
• Review Article Peroxisome Proliferator-activated Receptors: " Key " Regulators of Neuroinflammation after Traumatic Brain Injury

  year unknowncites this paper